Xenetic Biosciences, Inc. (NASDAQ:XBIO) | Finanzwire

Basculer en Français

9475	Companies
185456	Keywords
117803	Articles
99310	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

BRIEF

published on 11/19/2025 at 14:50, 15 days 23 hours ago

Xenetic Biosciences Extends Collaboration with Scripps Research

Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE

published on 11/19/2025 at 14:45, 15 days 23 hours ago

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers

Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF

published on 11/13/2025 at 14:50, 21 days 23 hours ago

Xenetic Biosciences Reports Q3 2025 Financial Results

Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE

published on 11/13/2025 at 14:45, 21 days 23 hours ago

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations

Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF

published on 10/10/2025 at 15:35, 1 month 25 days ago

Xenetic Biosciences Announces $4.5 Million Stock Offering

Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
PRESS RELEASE

published on 10/10/2025 at 15:30, 1 month 25 days ago

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
Xenetic Biosciences, Inc. announces pricing of underwritten stock offering, aiming to raise $4.5 million for immuno-oncology technologies. Canaccord Genuity acts as bookrunner

Xenetic Biosciences Stock Offering Immuno-oncology Technologies Canaccord Genuity S-3 Registration Statement
BRIEF

published on 08/13/2025 at 14:05, 3 months 22 days ago

Xenetic Biosciences Reports Q2 2025 Financial Results

Financial Results Xenetic Biosciences Q2 2025 DNase I Development Partnership Expansions
PRESS RELEASE

published on 08/13/2025 at 14:00, 3 months 22 days ago

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
Xenetic Biosciences, Inc. reports Q2 2025 results, expands partnership with The Scripps Research Institute for DNase I with CAR T-cell therapies and ends quarter with $4.8M cash

Financial Results Xenetic Biosciences DNase I The Scripps Research Institute CAR T-cell Therapies
BRIEF

published on 07/30/2025 at 15:05, 4 months 5 days ago

Xenetic Biosciences Collaborates with PeriNess for Lymphoma Study

Clinical Study Immuno-oncology DNase I Therapy CAR T-cell Large B Cell Lymphoma
PRESS RELEASE

published on 07/30/2025 at 15:00, 4 months 5 days ago

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
Xenetic Biosciences collaborates with PeriNess for an exploratory clinical study of DNase I with anti-CD19 CAR T cells in large B cell lymphoma patients at Tel Aviv Sourasky Medical Center

Xenetic Biosciences DNase I PeriNess Large B Cell Lymphoma Anti-CD19 CAR T Cells

1 2 ... 6

Accesswire

Published on 12/05/2025 at 02:35, 11 hours 19 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 11 hours 24 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 12 hours 54 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 49 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 54 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 13:45, 9 minutes ago

BingX Introduces Recurring Buy to Help Users Ride Out Crypto Market Swings
Published on 12/05/2025 at 13:00, 54 minutes ago

Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 54 minutes ago

Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 49 minutes ago

Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 54 minutes ago

CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre

Les Echos

Published on 12/05/2025 at 08:45, 5 hours 9 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 19 hours 54 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 20 hours 9 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 20 hours 10 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 6 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE